Seventeen patients with Cushing’s disease (CD) were treated from 1978 to 2000. There were 11 males and 6 females aged 6.8–18.8 years (mean age 13.0 ± 5.9 years). Presenting features were: weight gain (100%); growth failure (71%); hirsutism (53%); striae (53%); hypertension (47%). Mean age of patients with striae was 15.2 ± 2.3 years, without striae 10.3 ± 3.3 years. Median height SDS was –1.81 (range –0.28 to –4.17), 53% having height SDS < –1.8. The height velocity in 6 subjects was subnormal (0.9–3.8 cm/year). Median BMI SDS was 2.29 (range 1.72–5.06). Cushing’s disease was confirmed by detectable serum ACTH, median 28 ng/l (range 12–99, NR <10–50) (n = 15); loss of cortisol circadian rhythm values at midnight ranging from 216 to 1,080 nmol/l (NR <50) (n = 15); lack of cortisol suppression (NV < 50 nmol/l) during low-dose dexamethasone suppression test (LDDST) (0.5 mg 6-hourly × 8) (n = 14); and >50% suppression of cortisol compared with the basal value during high-dose dexamethasone suppression test (HDDST) (2 mg 6-hourly × 8) (n = 14). A CRH test (1 µg/kg i.v.) showed an increase of cortisol from 12 to 217% (median 73.5%) (n = 16). Pituitary imaging (CT/MRI) showed an image consistent with microadenoma in 6/17 patients, but there was concordance between pituitary imaging and surgical findings in 1/11 patients (9%). Inferior petrosal sinus sampling (IPSS) for ACTH after CRH was performed in 11 subjects (age 10.7–18.8 years). Central to peripheral ACTH ratios were >2 (2.5–157.2) in 10/11 patients. The inter-petrosal sinus ACTH gradient was >1.4 in 10 patients (2.1–20.8), indicating lateralization of ACTH secretion. In 10 patients (91%), the side of the tumour on IPSS was predictive of findings at surgery. Therapy consisted of transsphenoidal microadenomectomy (TSS) in 16 patients and bilateral adrenalectomy (1978) in 1. Following TSS alone, 7 patients were cured (cortisol <50 nmol/l) and 2 were in remission (cortisol <300 nmol/l), i.e. 56%. Seven had persisting hypercortisolaemia and underwent pituitary irradiation (4,500 cGy). Therapeutic outcome for a median of 8 years (0.5–24 years) resulted in cure of CD in 14/17 patients (82%) and remission in 1. Linear growth after TSS ± pituitary irradiation in 10 subjects showed no short-term catch-up growth, with peak growth hormone (GH) 0.5–20.9 mU/l to insulin tolerance test (ITT)/glucagon. Eight patients were treated with human growth hormone (hGH) (14 U/m2/week) combined in 3 with GnRH analogue. The mean final (n = 6) or latest (n = 4) height SDS was –1.36. The difference between final/latest height SDS and target height SDS was 0.93 ± 1.13, i.e. less (p = 0.005) than the difference between height SDS and target height SDS at presentation, i.e. 1.72 ± 1.26, indicating long-term catch-up growth.

Keywords:
Cushing’s disease, Pituitary microadenoma, Transsphenoidal surgery, Childhood/paediatric, Short stature
1.
Weber A, Trainer PJ, Grossman AB, Afshar F, Medbak S, Perry LA, Plowman PN, Rees LH, Besser GM, Savage MO: Investigation, management and therapeutic outcome in 12 cases of childhood and adolescent Cushing’s syndrome. Clin Endocrinol 1995;43:19–28.
2.
Savage MO, Besser GM: Cushing’s disease in childhood. Trends Endocrinol Metab 1996;7:213–216.
3.
Magiakou MA, Mastorakos G, Oldfield EH, Gomez MT, Doppman JL, Cutler GB, Nieman LK, Chrousos GP: Cushing’s syndrome in children and adolescents. Presentation, diagnosis, and therapy. New Engl J Med 1994;331:629–636.
4.
Newell-Price J, Trainer PJ, Besser GM, Grossman AB: The diagnosis and differential diagnosis of Cushing’s syndrome and pseudo-Cushing’s states. Endocr Rev 1998;19:647–672.
5.
Freeman JV, Cole TJ, Chinn S, Jones PR, White EM, Preece MA: Cross sectional stature and weight reference curves for the UK, 1990. Arch Dis Child 1995;73:17–24.
6.
Cole TJ, Freeman JV, Preece MA: Body mass index reference curves for the UK, 1990. Arch Dis Child 1995;73:25–29.
7.
Lienhardt A, Grossman AB, Hübner A, Dacie JE, Afshar F, Besser GM, Savage MO: Relative contributions of inferior petrosal sinus sampling and pituitary imaging in the investigation of children and adolescents with ACTH-dependent Cushing’s syndrome. 39th Annual ESPE Meeting, Brussels, September 2000 (abstract P1-232). Horm Res 2000;53(suppl 2):69.
8.
Oldfield EH, Doppman JL, Nieman LK, Chrousos GP, Miller DL, Katz DA, Cutler GB, Loriaux DL: Petrosal sinus sampling with and without corticotropin-releasing hormone for the differential diagnosis of Cushing’s syndrome. New Engl J Med 1991;325:897–905.
9.
Fahlbusch R, Honegger J, Buchfelder M: Neurosurgical management of Cushing’s disease in children; in Savage MO, Bourguignon J-P, Grossman AB (eds): Frontiers in Paediatric Neuroendocrinology. Oxford, Blackwell Science, 1994, pp 68–72.
10.
Devoe DJ, Miller WL, Conte FA, Kaplan SL, Grumbach MM, Rosenthal SM, Wilson CB, Gitelman SE: Long-term outcome in children and adolescents after transsphenoidal surgery for Cushing’s disease. J Clin Endocrinol Metab 1997;82:3196–3202.
11.
Trainer PJ, Lawrie HS, Verhelst J, Howlett TA, Lowe DG, Grossman AB, Savage MO, Afshar F, Besser GM: Transsphenoidal resection in cushing’s disease: Undetectable serum cortisol as the definition of successful treatment. Clin Endocrinol 1993;38:73–78.
12.
Jennings AS, Liddle GW, Orth DN: Results of treating childhood Cushing’s disease with pituitary irradiation. New Engl J Med 1977;297:957–962.
13.
Thoren M, Rahn T, Hallengren B, Kaad PH, Nilsson KO, Ravn H, Ritzen M, Petersen KE, Aarskog D: Treatment of cushing’s disease in childhood and adolescence by stereotactic pituitary irradiation. Acta Paediatr Scand 1986;75:388–395.
14.
Howlett TA, Plowman PN, Wass JA, Rees LH, Jones AE, Besser GM: Megavoltage pituitary irradiation in the management of cushing’s disease and Nelson’s syndrome: Long-term follow-up. Clin Endocrinol 1989;31:309–323.
15.
Magiakou MA, Mastorakos G, Chrousos GP: Final stature in patients with endogenous Cushing’s syndrome. J Clin Endocrinol Metab 1994;79:1082–1085.
16.
Johnston LB, Grossman AB, Plowman PN, Besser GM, Savage MO: Normal final height and apparent cure after pituitary irradiation for Cushing’s disease in childhood: Long-term follow-up of anterior pituitary function. Clin Endocrinol 1998:48;663–667.
17.
Lebrethon MC, Grossman AB, Afshar F, Plowman PN, Besser GM, Savage MO: Linear growth and final height after treatment for Cushing’s disease in childhood. J Clin Endocrinol Metab 2000:85;3262–3265.
18.
Magiakou MA, Mastorakos G, Gomez MT, Rose SR, Chrousos GP: Suppressed spontaneous and stimulated growth hormone secretion in patients with Cushing’s disease before and after surgical cure. J Clin Endocrinol Metab 1994;78:131–137.
19.
Leinung MC, Kane LA, Scheithauer BW, Carpenter PC, Laws ER, Zimmerman D: Long term follow-up of transsphenoidal surgery for the treatment of Cushing’s disease in childhood. J Clin Endocrinol Metab 1995;80:2475–2479.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.